Christiane A. Geluk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christiane A. Geluk has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Felix Zijlstra
University Medical Center Groningen
4 shared publicationsHans L. Hillege
University Medical Center Groningen
3 shared publications- Wiek H. van Gilst
University of Groningen, University Medical Center Groningen, Department of Cardiology, Groningen, The Netherlands
3 shared publications - Matthijs Oudkerk
Institute for Diagnostic Accuracy, Groningen, the Netherlands; Faculty of Medical Sciences, University of Groningen, Groningen, the Netherlands
2 shared publications Paul E. de Jong
University Medical Center Groningen
2 shared publicationsRené A. Tio
University Medical Center Groningen
2 shared publications
Latest Publications
- 1 January 2008
- Published by Elsevier in Atherosclerosis
- Vol. 196 (1) , 372-382
C-reactive protein and angiographic characteristics of stable and unstable coronary artery disease: Data from the prospective PREVEND cohort
- 1 January 2008
- Published by Elsevier in Atherosclerosis
- Vol. 196 (1) , 372-382
C-reactive protein and angiographic characteristics of stable and unstable coronary artery disease: Data from the prospective PREVEND cohort
- Open Access
- 28 September 2007
- Published by Springer Nature in European Radiology
- Vol. 18 (2) , 244-252
Measurement of coronary calcium scores by electron beam computed tomography or exercise testing as initial diagnostic tool in low-risk patients with suspected coronary artery disease
We determined the efficiency of a screening protocol based on coronary calcium scores (CCS) compared with exercise testing in patients with suspected coronary artery disease (CAD), a normal ECG and troponin levels. Three-hundred-and-four patients were enrolled in a screening protocol including CCS by electron beam computed tomography (Agatston score), and exercise testing. Decision-making was based on CCS. When CCS≥400, coronary angiography (CAG) was recommended. When CCSP<0.0001). In conclusion, measurement of CCS is an appropriate initial screening test in a well-defined low-risk population with suspected CAD.
- 28 September 2007
- Published by Springer Nature in European Radiology
- Vol. 18 (2) , 244-252
Open AccessMeasurement of coronary calcium scores by electron beam computed tomography or exercise testing as initial diagnostic tool in low-risk patients with suspected coronary artery disease
We determined the efficiency of a screening protocol based on coronary calcium scores (CCS) compared with exercise testing in patients with suspected coronary artery disease (CAD), a normal ECG and troponin levels. Three-hundred-and-four patients were enrolled in a screening protocol including CCS by electron beam computed tomography (Agatston score), and exercise testing. Decision-making was based on CCS. When CCS≥400, coronary angiography (CAG) was recommended. When CCSP<0.0001). In conclusion, measurement of CCS is an appropriate initial screening test in a well-defined low-risk population with suspected CAD.
- Open Access
- 13 July 2007
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 7 (1) , 1-9
Measurement of coronary calcium scores or exercise testing as initial screening tool in asymptomatic subjects with ST-T changes on the resting ECG: an evaluation study
Asymptomatic subjects at intermediate coronary risk may need diagnostic testing for risk stratification. Both measurement of coronary calcium scores and exercise testing are well established tests for this purpose. However, it is not clear which test should be preferred as initial diagnostic test. We evaluated the prevalence of documented coronary artery disease (CAD) according to calcium scores and exercise test results. Asymptomatic subjects with ST-T changes on a rest ECG were selected from the population based PREVEND cohort study and underwent measurement of calcium scores by electron beam tomography and exercise testing. With calcium scores ≥10 or a positive exercise test, myocardial perfusion imaging (MPS) or coronary angiography (CAG) was recommended. The primary endpoint was documented obstructive CAD (≥50% stenosis). Of 153 subjects included, 149 subjects completed the study protocol. Calcium scores ≥400, 100–399, 10–99 and <10 were found in 16, 29, 18 and 86 subjects and the primary endpoint was present in 11 (69%), 12 (41%), 0 (0%) and 1 (1%) subjects, respectively. A positive, nondiagnostic and negative exercise test was present in 33, 27 and 89 subjects and the primary endpoint was present in 13 (39%), 5 (19%) and 6 (7%) subjects, respectively. Receiver operator characteristics analysis showed that the area under the curve, as measure of diagnostic yield, of 0.91 (95% CI 0.84–0.97) for calcium scores was superior to 0.74 (95% CI 0.64–0.83) for exercise testing (p = 0.004). Measurement of coronary calcium scores is an appropriate initial non-invasive test in asymptomatic subjects at increased coronary risk.
- 13 July 2007
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 7 (1) , 1-9
Open AccessMeasurement of coronary calcium scores or exercise testing as initial screening tool in asymptomatic subjects with ST-T changes on the resting ECG: an evaluation study
Asymptomatic subjects at intermediate coronary risk may need diagnostic testing for risk stratification. Both measurement of coronary calcium scores and exercise testing are well established tests for this purpose. However, it is not clear which test should be preferred as initial diagnostic test. We evaluated the prevalence of documented coronary artery disease (CAD) according to calcium scores and exercise test results. Asymptomatic subjects with ST-T changes on a rest ECG were selected from the population based PREVEND cohort study and underwent measurement of calcium scores by electron beam tomography and exercise testing. With calcium scores ≥10 or a positive exercise test, myocardial perfusion imaging (MPS) or coronary angiography (CAG) was recommended. The primary endpoint was documented obstructive CAD (≥50% stenosis). Of 153 subjects included, 149 subjects completed the study protocol. Calcium scores ≥400, 100–399, 10–99 and <10 were found in 16, 29, 18 and 86 subjects and the primary endpoint was present in 11 (69%), 12 (41%), 0 (0%) and 1 (1%) subjects, respectively. A positive, nondiagnostic and negative exercise test was present in 33, 27 and 89 subjects and the primary endpoint was present in 13 (39%), 5 (19%) and 6 (7%) subjects, respectively. Receiver operator characteristics analysis showed that the area under the curve, as measure of diagnostic yield, of 0.91 (95% CI 0.84–0.97) for calcium scores was superior to 0.74 (95% CI 0.64–0.83) for exercise testing (p = 0.004). Measurement of coronary calcium scores is an appropriate initial non-invasive test in asymptomatic subjects at increased coronary risk.
- 1 April 2007
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 15 (4) , 133-141
Clinical characteristics, cardiac events and coronary angiographic findings in the prospective PREVEND cohort: an observational study
- 1 April 2007
- Published by Springer Nature in Netherlands Heart Journal
- Vol. 15 (4) , 133-141
Clinical characteristics, cardiac events and coronary angiographic findings in the prospective PREVEND cohort: an observational study
- Open Access
- 17 October 2005
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 27 (9) , 1127-1128
Gatekeeper for coronary angiography
We would like to compliment Hoilund-Carlsen and colleagues on their well-designed study on myocardial perfusion scintigraphy (MPS) as gatekeeper for coronary angiography.1 However, we have some doubts with regard to the use of MPS in a not-low-risk population. In this selection of patients scheduled for coronary angiography, obstructive coronary artery disease (CAD) was present in half of the population. This is more than twice the prevalence found in populations screened for acute chest pain.2 In such not-low-risk populations, it has been advised to use a test with high sensitivity to identify all patients with the most severe forms of disease in order to improve event-free survival and cost-effectiveness at a long term.3 In our opinion, a sensitivity of 81% for obstructive CAD and 94% for three-vessel disease, as was found by Hoilund-Carlsen and colleagues, is too low to incorporate MPS as effective gatekeeper in a pre-coronary angiography strategy.
- 17 October 2005
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 27 (9) , 1127-1128
Open AccessGatekeeper for coronary angiography
We would like to compliment Hoilund-Carlsen and colleagues on their well-designed study on myocardial perfusion scintigraphy (MPS) as gatekeeper for coronary angiography.1 However, we have some doubts with regard to the use of MPS in a not-low-risk population. In this selection of patients scheduled for coronary angiography, obstructive coronary artery disease (CAD) was present in half of the population. This is more than twice the prevalence found in populations screened for acute chest pain.2 In such not-low-risk populations, it has been advised to use a test with high sensitivity to identify all patients with the most severe forms of disease in order to improve event-free survival and cost-effectiveness at a long term.3 In our opinion, a sensitivity of 81% for obstructive CAD and 94% for three-vessel disease, as was found by Hoilund-Carlsen and colleagues, is too low to incorporate MPS as effective gatekeeper in a pre-coronary angiography strategy.
- Open Access
- 8 April 2005
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 26 (13) , 1314-1320
Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial
Aims Microalbuminuria frequently clusters with the metabolic syndrome and may identify subjects at increased coronary risk. Statin treatment may reduce the incidence of major adverse cardiac events in subjects with the metabolic syndrome, but evidence is limited. We evaluated the impact of pravastatin treatment on the incidence of major adverse cardiac events in microalbuminuric subjects with the metabolic syndrome. Methods and results This substudy of the PREVEND Intervention Trial (a randomized, placebo-controlled trial with a 2×2 factorial design) included 864 microalbuminuric subjects, who were randomized to fosinopril 20 mg or matching placebo and pravastatin 40 mg or matching placebo (mean follow-up 46 months). The metabolic syndrome was defined according to the NCEP ATPIII-report. Subjects with or without the metabolic syndrome were characterized by a higher age, male sex, and increased albuminuria. The incidence of major adverse cardiac events in subjects with the metabolic syndrome [9.1%; 95% confidence interval (CI) 6.0–13.0%] was increased vs. those without [3.6%; 95% CI 2.3–5.5%; P=0.007). Pravastatin treatment lowered the incidence of major adverse cardiac events in subjects with the metabolic syndrome after adjustment for age and sex (hazard ratio=0.39; 95% CI 0.17–0.89; P=0.025). Conclusion This study supports the use of statins in microalbuminuric subjects with the metabolic syndrome to reduce the incidence of major adverse cardiac events.
- 8 April 2005
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 26 (13) , 1314-1320
Open AccessImpact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial
Aims Microalbuminuria frequently clusters with the metabolic syndrome and may identify subjects at increased coronary risk. Statin treatment may reduce the incidence of major adverse cardiac events in subjects with the metabolic syndrome, but evidence is limited. We evaluated the impact of pravastatin treatment on the incidence of major adverse cardiac events in microalbuminuric subjects with the metabolic syndrome. Methods and results This substudy of the PREVEND Intervention Trial (a randomized, placebo-controlled trial with a 2×2 factorial design) included 864 microalbuminuric subjects, who were randomized to fosinopril 20 mg or matching placebo and pravastatin 40 mg or matching placebo (mean follow-up 46 months). The metabolic syndrome was defined according to the NCEP ATPIII-report. Subjects with or without the metabolic syndrome were characterized by a higher age, male sex, and increased albuminuria. The incidence of major adverse cardiac events in subjects with the metabolic syndrome [9.1%; 95% confidence interval (CI) 6.0–13.0%] was increased vs. those without [3.6%; 95% CI 2.3–5.5%; P=0.007). Pravastatin treatment lowered the incidence of major adverse cardiac events in subjects with the metabolic syndrome after adjustment for age and sex (hazard ratio=0.39; 95% CI 0.17–0.89; P=0.025). Conclusion This study supports the use of statins in microalbuminuric subjects with the metabolic syndrome to reduce the incidence of major adverse cardiac events.